Aura Biosciences Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Selling, General & Admin	19.98	19.76	18.06	10.09	4.16	4.52
Research & Development	67.88	65.23	42.24	25.16	18.04	19.62
Operating Expenses	87.86	84.99	60.3	35.25	22.21	24.14
Operating Income	-87.86	-84.99	-60.3	-35.25	-22.21	-24.14
Interest Expense / Income	0	0	0	0	0	0.01
Other Expense / Income	-9.4	-8.72	-1.53	10.94	-	0.06
Pretax Income	-78.47	-76.27	-58.76	-46.19	-22.21	-24.2
Income Tax	0.18	0.14	0	0	0	0
Net Income	-78.65	-76.41	-58.76	-46.19	-22.21	-24.2
Preferred Dividends	0	0	0	0	7.93	6.03
Net Income Common	-78.65	-76.41	-58.76	-46.19	-30.13	-30.23
Shares Outstanding (Basic)	49	40	30	5	0	5
Shares Outstanding (Diluted)	49	40	30	5	0	5
Shares Change	30.88%	32.34%	480.18%	1305.21%	-92.08%	-
EPS (Basic)	-1.86	-1.93	-1.96	-8.95	-82.06	-6.52
EPS (Diluted)	-1.86	-1.93	-1.96	-8.95	-82.06	-6.52
Free Cash Flow	-72.58	-64.56	-55.7	-34.54	-25.09	-22.89
Free Cash Flow Per Share	-1.47	-1.63	-1.86	-6.69	-68.33	-4.94
EBITDA	-75	-73.14	-56.62	-45.36	-21.38	-23.69
Depreciation & Amortization	3.46	3.13	2.15	0.83	0.83	0.51
EBIT	-78.47	-76.27	-58.76	-46.19	-22.21	-24.2

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).